Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases
暂无分享,去创建一个
[1] Ron Goeree,et al. A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment , 2012, PharmacoEconomics.
[2] Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] J. Latour‐Pérez,et al. Cost Effectiveness of Fondaparinux in Non-ST-Elevation Acute Coronary Syndrome , 2012, PharmacoEconomics.
[4] M Sculpher,et al. Health Technology Assessment: Development and Future , 2009 .
[5] N. Maniadakis,et al. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. , 2005, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[6] Natasha K. Stout,et al. Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines , 2012, PharmacoEconomics.
[7] Richard G. White,et al. Calibrating Models in Economic Evaluation , 2012, PharmacoEconomics.
[8] L. Goldman,et al. Health and Economic Benefits of Increased β-Blocker Use Following Myocardial Infarction , 2000 .
[9] Kristian Bolin,et al. Economic Evaluation of Smoking-Cessation Therapies , 2012, PharmacoEconomics.
[10] D. Owens,et al. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. , 2003, The American journal of medicine.
[11] J Karnon,et al. Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.
[12] J. Herlitz,et al. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden , 2010, Applied health economics and health policy.
[13] William Hollingworth,et al. Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[14] M. Eckman,et al. Cost-effectiveness of telemetry for hospitalized patients with low-risk chest pain. , 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[15] M. Ridao-López,et al. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] J. Brazier,et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[17] L. Coupal,et al. Estimating the Cost Effectiveness of Ramipril used for Specific Clinical Indications , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[18] Uwe Siebert,et al. Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease , 2011, PharmacoEconomics.
[19] Anya Okhmatovskaia,et al. Validation of population-based disease simulation models: a review of concepts and methods , 2010, BMC public health.
[20] H. Kohli. Scottish Medicines Consortium. , 2005, The National medical journal of India.
[21] A. Smala,et al. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany , 2008, Current medical research and opinion.
[22] Jonathan Karnon,et al. Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions , 2011, PharmacoEconomics.
[23] P Tappenden,et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. , 2007, Health technology assessment.
[24] M J Buxton,et al. Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.
[25] Jonathan Karnon,et al. A Critical Review of Model-Based Economic Studies of Depression , 2012, PharmacoEconomics.
[26] D. Cameron,et al. Edinburgh Research Explorer Health economics in drug development: efficient research to inform healthcare funding decisions , 2022 .
[27] M Sculpher,et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.
[28] A Gafni,et al. Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. , 1999, Journal of evaluation in clinical practice.
[29] L. Coupal,et al. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. , 2000, Journal of cardiopulmonary rehabilitation.
[30] Jonathan Karnon,et al. Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[31] J. Homer,et al. A system dynamics model for planning cardiovascular disease interventions. , 2010, American journal of public health.
[32] Bartele Marten Sybrens. Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention , 2015 .
[33] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] L. Goldman,et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. , 2000, JAMA.
[35] Karl Claxton,et al. Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.
[36] B. Jönsson,et al. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention , 2005, The European Journal of Health Economics.
[37] C. Fidler,et al. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice , 2010, Advances in therapy.
[38] Sarah Wordsworth,et al. Applied Methods of Cost-Effectiveness Analysis in Healthcare , 2010 .
[39] Simon Dixon,et al. Testing the Validity of Cost-Effectiveness Models , 2000, PharmacoEconomics.
[40] Ping Zhang,et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[41] Karen M Kuntz,et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. , 2002, The New England journal of medicine.
[42] Milton C. Weinstein,et al. Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.
[43] P. Tappenden,et al. Continuing the multiple sclerosis risk sharing scheme is unjustified , 2010, BMJ : British Medical Journal.
[44] Paul A Scuffham,et al. Cost-effectiveness of coronary computed tomography and cardiac stress imaging in the emergency department: a decision analytic model comparing diagnostic strategies for chest pain in patients at low risk of acute coronary syndromes. , 2011, JACC. Cardiovascular imaging.
[45] Alan Brennan,et al. Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.
[46] E Goyder,et al. A review and critique of modelling in prioritising and designing screening programmes. , 2007, Health technology assessment.
[47] Mark Sculpher,et al. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis , 2007, Heart.
[48] Jill M Ferdinands,et al. Obstructive Lung Disease Models: What Is Valid? , 2008, COPD.
[49] J Hutton,et al. Modeling in economic evaluation: an unavoidable fact of life. , 1998, Health economics.
[50] Simon G Thompson,et al. Uncertainty and validation of health economic decision models. , 2009, Health economics.
[51] J. Avorn,et al. Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction , 2000, Annals of Internal Medicine.